DENTSPLY SIRONA INC (1XRAY.MI) Stock Fundamental Analysis
Europe - BIT:1XRAY - US24906P1093 - Common Stock
13.675 EUR
+13.68 (+Infinity%)
1XRAY gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 58 industry peers in the Health Care Equipment & Supplies industry. 1XRAY has a bad profitability rating. Also its financial health evaluation is rather negative. 1XRAY is cheap, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
1XRAY had positive earnings in the past year.
In the past year 1XRAY had a positive cash flow from operations.
1XRAY had negative earnings in 4 of the past 5 years.
Each year in the past 5 years 1XRAY had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of -15.01%, 1XRAY is not doing good in the industry: 69.23% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -45.17%, 1XRAY is doing worse than 73.85% of the companies in the same industry.
The Return On Invested Capital of 1XRAY (4.42%) is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for 1XRAY is below the industry average of 8.86%.
The 3 year average ROIC (3.90%) for 1XRAY is below the current ROIC(4.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.01% | ||
| ROE | -45.17% | ||
| ROIC | 4.42% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)3.9%
ROIC(5y)4.04%
1.3 Margins
The Operating Margin of 1XRAY (6.75%) is comparable to the rest of the industry.
In the last couple of years the Operating Margin of 1XRAY has declined.
Looking at the Gross Margin, with a value of 51.84%, 1XRAY is doing worse than 61.54% of the companies in the same industry.
1XRAY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.75% | ||
| PM (TTM) | N/A | ||
| GM | 51.84% |
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), 1XRAY is destroying value.
Compared to 1 year ago, 1XRAY has less shares outstanding
1XRAY has less shares outstanding than it did 5 years ago.
The debt/assets ratio for 1XRAY is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.06, we must say that 1XRAY is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.06, 1XRAY is doing worse than 67.69% of the companies in the same industry.
1XRAY has a debt to FCF ratio of 8.40. This is a slightly negative value and a sign of low solvency as 1XRAY would need 8.40 years to pay back of all of its debts.
1XRAY has a Debt to FCF ratio (8.40) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.79 indicates that 1XRAY is somewhat dependend on debt financing.
1XRAY has a Debt to Equity ratio of 0.79. This is in the lower half of the industry: 1XRAY underperforms 76.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 8.4 | ||
| Altman-Z | 1.06 |
ROIC/WACC0.58
WACC7.56%
2.3 Liquidity
1XRAY has a Current Ratio of 1.10. This is a normal value and indicates that 1XRAY is financially healthy and should not expect problems in meeting its short term obligations.
1XRAY has a worse Current ratio (1.10) than 72.31% of its industry peers.
1XRAY has a Quick Ratio of 1.10. This is a bad value and indicates that 1XRAY is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.76, 1XRAY is not doing good in the industry: 69.23% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.1 | ||
| Quick Ratio | 0.76 |
3. Growth
3.1 Past
The earnings per share for 1XRAY have decreased by -9.68% in the last year.
Measured over the past years, 1XRAY shows a decrease in Earnings Per Share. The EPS has been decreasing by -7.38% on average per year.
1XRAY shows a decrease in Revenue. In the last year, the revenue decreased by -5.61%.
1XRAY shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.17% yearly.
EPS 1Y (TTM)-9.68%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%2.38%
Revenue 1Y (TTM)-5.61%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-7.76%
3.2 Future
1XRAY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.35% yearly.
The Revenue is expected to grow by 1.07% on average over the next years.
EPS Next Y13.24%
EPS Next 2Y11.26%
EPS Next 3Y10.85%
EPS Next 5Y9.35%
Revenue Next Year-4.15%
Revenue Next 2Y-0.83%
Revenue Next 3Y0.44%
Revenue Next 5Y1.07%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 9.37 indicates a reasonable valuation of 1XRAY.
Based on the Price/Earnings ratio, 1XRAY is valued cheaper than 98.46% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.30. 1XRAY is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 7.62, the valuation of 1XRAY can be described as very cheap.
Based on the Price/Forward Earnings ratio, 1XRAY is valued cheaper than 96.92% of the companies in the same industry.
1XRAY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.73.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.37 | ||
| Fwd PE | 7.62 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1XRAY is valued cheaply inside the industry as 86.15% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, 1XRAY is valued cheaper than 90.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.29 | ||
| EV/EBITDA | 8.56 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.71
PEG (5Y)N/A
EPS Next 2Y11.26%
EPS Next 3Y10.85%
5. Dividend
5.1 Amount
1XRAY has a Yearly Dividend Yield of 4.00%.
1XRAY's Dividend Yield is rather good when compared to the industry average which is at 2.16. 1XRAY pays more dividend than 96.92% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.45, 1XRAY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4% |
5.2 History
On average, the dividend of 1XRAY grows each year by 11.21%, which is quite nice.
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
1XRAY has negative earnings and hence a negative payout ratio. The dividend may be in danger.
1XRAY's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP-14.21%
EPS Next 2Y11.26%
EPS Next 3Y10.85%
BIT:1XRAY (5/26/2025, 7:00:00 PM)
13.675
+13.68 (+Infinity%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners104.5%
Inst Owner ChangeN/A
Ins Owners0.33%
Ins Owner ChangeN/A
Market Cap2.73B
Analysts70.43
Price Target16.45 (20.29%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4% |
Yearly Dividend0.54
Dividend Growth(5Y)11.21%
DP-14.21%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.42%
Min EPS beat(2)-40.52%
Max EPS beat(2)45.37%
EPS beat(4)2
Avg EPS beat(4)1.53%
Min EPS beat(4)-40.52%
Max EPS beat(4)45.37%
EPS beat(8)3
Avg EPS beat(8)2.46%
EPS beat(12)6
Avg EPS beat(12)5.25%
EPS beat(16)8
Avg EPS beat(16)3.68%
Revenue beat(2)1
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-3.62%
Max Revenue beat(2)0.77%
Revenue beat(4)1
Avg Revenue beat(4)-1.66%
Min Revenue beat(4)-3.62%
Max Revenue beat(4)0.77%
Revenue beat(8)3
Avg Revenue beat(8)-1.57%
Revenue beat(12)5
Avg Revenue beat(12)-1.53%
Revenue beat(16)6
Avg Revenue beat(16)-1.71%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.37 | ||
| Fwd PE | 7.62 | ||
| P/S | 0.84 | ||
| P/FCF | 11.29 | ||
| P/OCF | 7.08 | ||
| P/B | 1.56 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.56 |
EPS(TTM)1.46
EY10.68%
EPS(NY)1.8
Fwd EY13.13%
FCF(TTM)1.21
FCFY8.86%
OCF(TTM)1.93
OCFY14.12%
SpS16.21
BVpS8.76
TBVpS-3.64
PEG (NY)0.71
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.01% | ||
| ROE | -45.17% | ||
| ROCE | 5.9% | ||
| ROIC | 4.42% | ||
| ROICexc | 4.88% | ||
| ROICexgc | 18.55% | ||
| OM | 6.75% | ||
| PM (TTM) | N/A | ||
| GM | 51.84% | ||
| FCFM | 7.48% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)3.9%
ROIC(5y)4.04%
ROICexc(3y)4.14%
ROICexc(5y)4.27%
ROICexgc(3y)14.85%
ROICexgc(5y)19.88%
ROCE(3y)5.38%
ROCE(5y)5.49%
ROICexcg growth 3Y-31.16%
ROICexcg growth 5Y-12.42%
ROICexc growth 3Y-13.44%
ROICexc growth 5Y-4.44%
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
F-Score3
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 8.4 | ||
| Debt/EBITDA | 2.69 | ||
| Cap/Depr | 48.25% | ||
| Cap/Sales | 4.44% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.7% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.1 | ||
| Quick Ratio | 0.76 | ||
| Altman-Z | 1.06 |
F-Score3
WACC7.56%
ROIC/WACC0.58
Cap/Depr(3y)46.81%
Cap/Depr(5y)41.51%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.68%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%2.38%
EPS Next Y13.24%
EPS Next 2Y11.26%
EPS Next 3Y10.85%
EPS Next 5Y9.35%
Revenue 1Y (TTM)-5.61%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-7.76%
Revenue Next Year-4.15%
Revenue Next 2Y-0.83%
Revenue Next 3Y0.44%
Revenue Next 5Y1.07%
EBIT growth 1Y-11.93%
EBIT growth 3Y-28.45%
EBIT growth 5Y-13.75%
EBIT Next Year49.44%
EBIT Next 3Y19.3%
EBIT Next 5Y10.5%
FCF growth 1Y7.34%
FCF growth 3Y-18.29%
FCF growth 5Y-11.45%
OCF growth 1Y9.93%
OCF growth 3Y-11.14%
OCF growth 5Y-6.32%